Innate Pharma (IPHA) announced that its supervisory board has appointed Jonathan Dickinson as the company’s new CEO and chairman of the executive board, effective November 1. Jonathan Dickinson succeeds Herve Brailly, co-founder of the company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as executive VP and general manager, Europe at Incyte (INCY). Herve Brailly, current interim CEO, will stay for the next few months in an advisory role to ensure a smooth transition. It will be proposed that Brailly joins the board at the next opportunity.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA: